United Therapeutics Chairperson & CEO Martine Rothblatt Executes 10b5-1 Option Exercise and Sale

Insider Transaction Overview

On September 9, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp ($UTHR), executed transactions consisting of the exercise of stock options for 9,500 shares at $117.76 per share and the subsequent sale of all 9,500 common shares across multiple price tranches ranging from $493.81 to $509.00 per share.

Key Transaction Highlights

• Type: Stock Option Exercise & Open Market Sale (Rule 10b5-1 Trading Plan)
• Shares Sold: 9,500 shares
• Gross Sale Proceeds: ~$4.77 million (average price of ~$501.84/share)
• Option Cost Basis: $117.76/share ($1,118,720 total exercise cost)
• Net Profit Pre-Tax: ~$3.65 million
• Ownership Structure: The transactions were conducted indirectly via a family trust.

Plan & Context

• 10b5-1 Plan: The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan is scheduled to terminate upon the earlier of the exercise of 1,734,410 options (expiring March 15, 2027) or December 31, 2026.
• Remaining Holdings: Following the sale, Dr. Rothblatt retains substantial equity holdings, including 324,443 shares in this trust, 40,513 directly owned shares, and hundreds of thousands of additional shares and options held across other family trusts and accounts.

Significance

The trading significance is assessed as Low due to the routine, programmatic nature of the transactions under an established Rule 10b5-1 plan to exercise expiring stock options.